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ABSTRACT
The rat tropomyosin 1 gene gives rise to two mRNAs encoding rat fibroblast TM-1 and skeletal
muscle beta-tropomyosin via an alternative splicing mechanism. The gene is comprised of 11 exons.
Exons 1 through 5 and exons 8 and 9 are common to all mRNAs expressed from this gene. Exons
6 and 11 are used in fibroblasts as well as smooth muscle whereas exons 7 and 10 are used exclusively
in skeletal muscle. In the present studies we have focused on the mutually exclusive internal alternative
splice choice involving exon 6 (fibroblast-type splice) and exon 7 (skeletal muscle-type splice). To
study the mechanism and regulation of alternative splice site selection we have characterized the
branch points used in processing of the tropomyosin pre-mRNAs in vitro using nuclear extracts obtained
from HeLa cells. Splicing of exon 5 to exon 6 (fibroblast-type splice) involves the use of three branch
points located 25, 29, and 36 nucleotides upstream of the 3' splice site of exon 6. Splicing of exon
6 (fibroblast-type splice) or exon 7 (skeletal muscle type-splice) to exon 8 involves the use of the
same branch point located 24 nucleotides upstream of this shared 3' splice site. In contrast, the splicing
of exon 5 to exon 7 (skeletal muscle-type splice) involves the use of three branch sites located 144,
147 and 153 nucleotides, upstream of the 3' splice site of exon 7. In addition, the pyrimidine content
of the region between these unusual branch points and the 3' splice site of exon 7 was found to
be greater than 80%. These studies raise the possibility that the use of branch points located a long
distance from a 3' splice site may be an essential feature of some alternatively spliced exons. The
possible significance of these unusual branch points as well as a role for the polypyrimidine stretch
in intron 6 in splice site selection are discussed.
INTRODUCTION
The formation of a mature mRNA from a primary transcript generally requires excision
of intervening sequences (introns) as well as cleavage and polyadenylation at the 3' end.
Considerable progress has been made in recent years concerning the mechanisms and
biochemistry of pre-mRNA processing (for reviews see references 1—3). The development
of systems that accurately splice exogenous pre-mRNA in vitro has permitted a biochemical
analysis of the splicing reaction (4-6). The overall splicing reaction between two exons
can be described as occurring in two stages (6—9). In the first stage, a 5' exon is cleaved
and two intermediates are formed: a 5' exon with a 3' hydroxyl end and an RNA species
containing the intron sequence and 3' exon in which the 5' terminal guanosine nucleotide
of the intron is covalently linked to a residue, usually an adenosine, located 18-40
nucleotides upstream of the 3' splice site via a 2'-5' phosphodiester bond. In the second
stage, cleavage at the 3' splice site results in the release of a lariat intron and concomitantly
the two exons are ligated together.
The identification of sequences in the pre-mRNA required for accurate and efficient
splicing has provided important information about the mechanism of the splicing reaction.
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The 5' splice site consensus sequence AG/GTPuAGT, has been shown to interact with
the 5' end of the Ul small nuclear RNA (10—14). The 3' splice site consensus sequence
(Py)nNPyAG/G (10,11) interacts with several cellular factors, whose precise nature has
not been completely established. One of these, however, is a A 70-100 Kd protein, which
is probably associated with U5 snRNP (15,16). Analysis of the branch points of a number
of cellular and viral genes identified a loosely conserved sequence PyNPyTPuAPy, with
the adenosine residue serving as the site of branch formation (17-19). U2 snRNP is thought
to interact with the pre-mRNA at the branch point region, perhaps by direct base pairing
with the pre-mRNA (13, 20-22). A factor termed U2AF (U2 snRNP auxiliary factor)
has been reported to be necessary for the binding of U2 snRNP to the branch point and
splicing complex assembly (23).
While minimal sequence requirements have been established for splicing in simple
transcription units, it is unlikely that these sequences alone account for the choice between
alternative splice sites in complex transcription units. How alternative splice sites are selected
is not known. Sequence comparisons between splice junctions of alternative and constitutive
exons have failed to identify any significant differences (24). This suggests that the regulation
of splice site selection in transcripts containing alternative 5' or 3' splice sites involves
other cis-acting elements. Studies of alternatively spliced genes have identified a number
of features in the pre-mRNA which may be involved in alternative splice site selection.
These include intron size (25), the relative strengths of 5' splice sites (26), the pyrimidine
content of a 3' splice site (27), exon sequences (28-31), and multiple alternative branch
points (32—34). In addition, exon and intron sequences may be involved in the formation
of RNA secondary structures that could play a role in alternative RNA processing by
regulating the accessibility of different exons to the splicing machinery (35—41). A number
of studies have also suggested the existence of cell type-specific factors that interact with
sequence elements in the pre-mRNA to promote differential splice site selection (40,42).
However, the identity of these putative trans-acting factors and the sequences they recognize
to regulate alternative splicing remain largely unknown.
To determine if the splicing pathways of alternatively spliced exons exhibit mechanistic
differences compared to simple transcription units a number of studies have characterized
the intermediates involved in alternative splice site selection (32,34,43). Studies of alternative
splicing involving SV40 and adenovirus RNAs have demonstrated that multiple branch
points are associated with the processing of these pre-mRNAs (32,34). The expression
SV40 large T and small t RNAs involves the joining of alternative 5' splice sites to a
single shared 3' splice site. Splicing of large T RNA involved the use of one of six different
branch sites located 18-32 nucleotides from the 3' splice site (32). On the other hand
splicing of small t RNA involved the use of a single branch nucleotide located 18 nucleotides
upstream of the 3' splice junction (32). The adenovirus El A primary transcript is
differentially spliced to yield five mRNAs that have been designated 13S, 12S, 1 IS, 10S,
and 9S mRNAs (44,45). Splicing of E1A pre-mRNA to generate 13S, 12S and 9S involves
the joining of alternative 5' splice sites to a shared 3' splice site. In contrast to studies
of large T splicing, formation of E1A 13S, 12S and 9S mRNAs use the same branch
adenosine residue located 28 nucleotides upstream of the common 3' splice site (43). By
contrast, generation of the El A 1 IS and 10S mRNAs, which uses the same 5' splice site
as the 9S RNA but are joined to a different 3' splice site, uses one of three branch points
located an unusually long distance 51, 55 or 59 nucleotides upstream of the 3' splice site
(34). These studies of viral pre-mRNAs raise the possibility that utilization of multiple
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Figure 1. Schematic diagram of the rat tropomyosin 1 gene. Open boxes represent common exons, hatched and
closed boxes represent tissue-specific exons as indicated. Horizontal lines represent introns; they are not drawn
to scale. The amino acids encoded by each exon are indicated. The CAP site and polyadenylation sites arc also
indicated.
branch points may be a common feature of alternatively spliced exons. However, little
information is currently available concerning branch point selection in alternative splicing
of cellular genes.
We have been using the rat tropomyosin 1 gene as a model to investigate the mechanism
of a type of developmental and tissue-specific alternative splicing (31,46). This gene is
comprised of 11 exons (Figure 1). Exons 1 through 5 and 8 and 9 are common to all
mRNAs expressed from this gene. Exons 6 and 11 are used in fibroblasts as well as smooth
muscle whereas exons 7 and 10 are used exclusively in skeletal muscle. Our previous studies
of tropomyosin pre-mRNA splicing in vitro revealed an ordered pathway of splicing in
which either internal alternatively spliced exon must first be joined to the downstream
common exon before they can be spliced to the upstream common exon (31). To determine
if splicing of these alternative exons involves the use of multiple branch sites we analyzed
the lariat intron products produced by processing of tropomyosin pre-mRNAs in vitro.
We find that splicing of the alternative exons 6 and 7 to the downstream common exon
is associated with the use the same lariat branch point. By contrast, alternative splicing
of exon 5 to the downstream alternative exons 6 and 7 is associated with the use of different
multiple branch points. Interestingly, the branch points used in splicing exon 5 to exon
7 (skeletal muscle-type splice) are located at an unusually long distance (144, 147, and
153 nucleotides) from the 3' splice site of exon 7. The potential significance of these




The DNA templates for use in in vitro transcription with SP6 polymerase are shown in
Figure 2. All are derived from the rat fibroblast TM-1 gene (46). pSP64-p2 was constructed
by deletion of sequences from the unique Clal site in exon 9 with Bal 31 to 17 nucleotides
3' of exon 8. The DNA was then digested at a unique Ball site in exon 5. The DNA was
modified with Hindm linkers and cloned into the Hindm site of SP64. Thus SP64-p2
contains an SP6 promoter with 14 nucleotides of plasmid sequence including the HindlH
linker following the SP6 RNA initiation site and 66 nucleotides of exon 5 and genomic
sequence extending 17 nucleotides 3' of exon 8. Plasmid pSP64-p4 was derived from
SP64-p2 by ligating the Ncol/Sall fragment of the cDNA clone encoding rat fibroblast
TM-1 (47) to the Ncol/Sall sites of pSP64-p2. Plasmid pSP64-p2(7/8) was derived from
pSP64-2 by removal of the intervening sequence between exons 7 and 8 using a 30
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Figure 2. SP6/Tropomyosin transcriptionai templates. The DNA templates for use in in vitro transcription with
SP6 polymerase are shown. All are derived from the internal region of the TM-1 gene (exons 5 through 8).
The arrows indicate the sites of transcription initiation with the SP6 sequences (cross-hatched regions) adjacent
to the SP6 promoter. In vitro transcription terminates at indicated restriction sites. In addition, a number of internal
restriction sites are also indicated that can be used for synthesis of truncated substrates. The boxes indicate positions
of exon 5 (constitutive), exon 6 (fibroblast and smooth muscle-specific), exon 7 (skeletal muscle-specific) and
exon 8 (constitutive). Lines represent each lntron. The number of nucleotides in each exon and intron are indicated.
nucleotide long deoxyoligonucleotide containing 15 nucleotides of exon 7 and 15 nucleotides
of exon 8 (48). Plasmid pSP64-p2p6 was constructed by joining the regions of the cDNA
encoding fibroblast TM-1 corresponding to exons 9 through 11 to pSP64-p2. Plasmid
pSP65-p6 was derived from pSP64-p2 by modifying the Ncol site in exon 6 of pSP64-p2
with EcoRI linkers, and the resulting EcoRI-HindHI fragment, containing sequences from
the middle of exon 6 through sequences downstream of exon 8, was ligated into
EcoRI/Hindm double-cut pSP65 plasmid DNA. Plasmid pSP65-p7 was derived from
pSP65-p6 by modifying the PstI site upstream of exon 7 with EcoRI linkers and removing
the upstream EcoRI/PstI fragment.
Synthesis of RNA and in vitro splicing
The 32P-labelled SP6/tropomyosin transcripts were synthesized in vitro and primed with
CAP analog as described (49). The 32P-labelled pre-mRNAs contained a small amount
of prematurely terminated transcripts, but their presence did not appear to affect the in
vitro splicing reactions and therefore the RNA substrates were not further purified.
HeLa cell nuclear extracts were prepared as described (6,50). In vitro splicing reactions
were carried out at 30° for the indicated times (0—240 min). Standard assay conditions
used for these studies consisted of 15 /*1 of nuclear extract in a final reaction volume of
25 y\ containing 1 mM MgCl2, 500 /iM ATP, 20 mM creatine phosphate, 2.7% (w/v)
polyvinyl alcohol, 15-30 ng pre-mRNA, 12.8 mM Hepes (pH 8), 14% (v/v) glycerol,
60 mM KCL, 0.12 mM EDTA and 0.7 mM DTT.
Analysis of processing products
After incubation for the indicated times the reactions were stopped by addition of a solution
containing SDS-proteinase K and the RNA recovered as described (6). The products of
the reaction were analyzed on denaturing urea-polyacrylamide gels. Intermediates were
distinguished from final products by their relative appearance and disappearance in time
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course experiments. Lariat RNAs were identified by their aberrant mobility on different
percentage polyacrylamide gels (7,8). In addition, RNAs containing lariats were verified
with treatment by a lariat debranching activity (51). Processing products were also analyzed
by primer-extension analysis. Primer extension analysis was carried out essentially as
described (52,53). Oligodeoxynucleotides complementary to sequences encoding amino
acids 198-204 within exon 6 (5'-GAGAGCCTGGTCCATGGTTC-3'), amino acids
198-204 within exon 7 (5'- CAAGTTGTTGGTAACAATTT-3'), amino acids 223-229
within exon 8 (5'-TCCAGAAGTTTGATCTCTTC-3'), the 3' end of intron 6
(5'-CTGCAGGGGCGTGTG-3') and at position - 9 4 through -110 nucleotides upstream
of the 3' splice site of exon 7 (5'-GAGGGGTGGCAGAGTGG-3') of the rat fibroblast
TM-1 gene were used as primers. Primers were end labelled with (gamma-32P)ATP using
T4 polynucleotide kinase. The primers were annealed to the RNA by incubation for 3
minutes at 55 °C, then 30 minutes at 37 °C in 30 microliters of primer extension buffer
(50 mM Tris-Cl pH 8.3, 140 mM KC1, 10 mM MgCl2). For primer extension, reactions
were transferred to 42 °C and supplemented with DTT (final concentration of 5 mM) and
deoxynucleotide triphosphates (final concentration of 0.5 mM) and 10 U of avian
myeloblastosis virus reverse transcriptase. After 30 min, the reactions were terminated
by addition of EDTA to a final concentration of 25 mM, and the radiolabelled pre-mRNA
was degraded by treatment with RNAse A prior to gel electrophoresis. In order to sequence
the primer extension products the standard splicing reactions were scaled up 10-30 fold,
the primer-extension products were resolved on sequencing gels and the bands cut out
of gels, recovered and subjected to sequence analysis (54). In some experiments DNA
sequence was determined by the dideoxy termination procedure (55).
RESULTS
Tropomyosin gene constructs used for generation of pre-mRNAs for in vitro splicing
We prepared a number of DNA templates designed to analyze the internal alternatively
spliced region of the rat tropomyosin 1 gene (Figure 2). The constructions used in the
present studies contain 1, 2 or 3 introns of the region between exons 5 through exon 8,
inserted downstream of the SP6 promoter.
Splicing of exon five to exon six (fibroblast-type splice)
To analyze the branch point used during splicing of exon 5 to exon 6 (fibroblast-type splice),
we used a pre-mRNA derived from pSP64-p4 linearized with Clal (Figure 2). We previously
demonstrated that exon 5 is spliced accurately and efficiently to exon 6 using this precursor
(31). The products of the in vitro splicing reactions with pre-mRNA transcripts from
pSP64-p4 linearized with Clal are shown in Figure 3. In this experiment RNA transcripts
were incubated in in vitro splicing reactions for 30 min, 45 min, 60 min, and 120 min.
Following the splicing reactions the RNA was divided and a portion was fractionated on
a 4% polyacrylamide-urea gel (Figure 3a). To identify the branched nucleotides, a portion
of the RNA was analyzed by primer extension. Reverse transcription has been shown to
stop at branch nucleotides (19). Half of the RNA (debranched Figure 3b) was incubated
in a HeLa S-100 fraction that contains a lariat debranching activity (51) prior to primer
extension analysis. The other half was analyzed directly (branched, Figure 3b). Primer
extension was performed using a 20 nucleotide long 32P-labelled deoxyoligonucleotide
complementary to sequences within exon 6. cDNA products were analyzed on an 8%
polyacrylamide-8M urea gel along with dideoxy sequence generated from the appropriate
single stranded M13 template (Figure 3b). As indicated in Figure 3b, a 129 nucleotide
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Figure 3. /n vitro splicing of exon five to exon six (fibroblasMype splice). (Panel A) Time course (rrrin) of formation
of spliced products from transcripts terminating at the Clal site of plasmid pSP64-p4. The 32P-RNA products
were separated in 4% denaturing pdyacrylamide gels. Schematic representation of products are indicated; the
boxes represent exon sequences and the lines intron sequences. (Panel B) The in vitro processing products shown
in panel A were analyzed by primer-extension using a 32P-labelled oligodeoxynucleotide primer specific for
sequences in exon 8. Part of the processed RNA was treated with debranching extract prior to reverse transcription
(lanes debranched). (panel B) The lariat-exon intermediate indicated in panel A was isolated and subjected to
primer extension analysis. Position of primer extension products corresponding to splice products and intermediates
are indicated. The primer extension products were separated 6n a 8% denaturing polyacrylamide gel and
clectrophoresed in parallel with dideoxy sequencing reactions performed using single stranded M13 templates
primed with the same ^P-labelled oligonucleotide primer to the right. The sequences corresponding to positions
23 through 40 nucleotides upstream from the 3 ' splice site and corresponding branch nucleotides are indicated.
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products appeared after 45 min incubation and increased in intensity with longer incubation
times. This product corresponds to the size of the primer extension product of exon 5
joined to exon 6. Three shorter primer extension products accumulated in a time dependent
manner, and disappeared after debranching. Debranching of the reaction products also
gave rise to a new cDNA product of 196 nucleotides, resulting from a run-off extension
at the 5' splice cleavage site of intron 5. A similar analysis with the isolated lariat-exon
intermediate confirmed that three branched nucleotides were associated with use of this
3' splice site (Figure 3b). Comparison of the dideoxynucleotide sequence with the primer
extension products indicates that the three branched nucleotides correspond to positions
25, 29, and 36 nucleotides upstream from the 3' splice site of exon 6. The relative intensity
of the primer extension products indicates that the branch sites at positions - 2 5 and -29
are preferred over the branch site at - 3 6 . In addition, the weak branch site at - 3 6 is
unusual in that it does not utilize an adenosine residue but corresponds to a undine residue.
Splicing of exon six to exon eight (fibroblast-type splice)
To analyze the branch point used during splicing of exon 6 to exon 8 we used precursor
RNA derived from pSP65-p6 linearized with Hindin (Figure 2). RNA transcripts were
incubated in in vitro splicing reactions for 30 min, 45 min, 60 min, and 120 min, and
the products were analyzed as described before. The RNA products were loaded on a 4%
polyacrylamide-urea gels (Figure 4a). We observed four processing products corresponding
to i) free exon 6, ii) exon 6 spliced to exon 8, iii) free lariat containing intron 6/exon
7/intron 7, and iv) the lariat containing intron 6/exon 7/intron 7/exon 8 sequences. Since
HeLa cells express the same isoform as rat fibroblasts, this is the normal splice pattern
expected if this pre-mRNA was being spliced in a cell type-specific manner. In addition,
there was no indication that either the 5' or 3' splice sites of exon 7 were utilized with
this substrate. To determine the location of the branch point, we carried out primer extension
analysis using a 20 nucleotide long 32P-labelled oligodeoxynucleotide primer
complementary to sequences in the middle of exon 8 (Figure 4b). Figure 4b shows the
time course of the reaction products analyzed by primer-extension analysis. One product
of 106 nucleotides appeared after 45 min incubation and increased in intensity with longer
incubation times. This product corresponded to the size of the primer extension product
expected if exon 6 was correctly joined to exon 8. We confirmed this observation at the
nucleotide sequence level, by direct sequencing of this primer extension product (data not
shown). We also observed a shorter primer extension product of approximately 70
nucleotides long that accumulated in a time dependent manner. This product corresponded
to a branch point sequence located 24 nucleotides upstream of the 3' splice site of exon
8. This product was found to be sensitive to treatment with debranching activity (see below,
Figure 6).
Splicing of exon seven to exon eight (skeletal muscle-type splice)
To analyze the branch point used during splicing of exon 7 to exon 8 we have used precursor
RNA derived from pSP65-p7 linearized with Hindin (Figure 2). RNA transcripts were
incubated in in vitro splicing reactions and a portion of the RNA was fractionated on a
4% polyacrylamide-urea gel (Figure 5a). We observed four processing products
corresponding to i) free exon 7, ii) exon 7 spliced to exon 8, iii) free lariat, and iv) the
lariat-exon 8 intermediate. Primer extension analysis was carried out using a 20 nucleotide
long ^-labelled oligodeoxynucleotide primer complementary to sequences in the middle
of exon 8 as a primer (Figure 5b). Figure 5b shows the time course of the reaction products
analyzed by primer extension analysis. One product of 142 nucleotides appeared after 45
5639
Downloaded from https://academic.oup.com/nar/article-abstract/17/14/5633/1058920
by Cold Spring Harbor Laboratory user
on 08 November 2017
Nucleic Acids Research




Figure 4. In vitro splicing of exon six to exon eight (fibroblast-type splice). (Panel A) Time course (min) of
formation of spliced products from transcripts terminating at the Sail site of plasmid pSP65-p6. The 32P-RNA
products were separated in 4% denaturing polyacrylamide/ gels. Schematic representation of products are indicated;
the boxes represent exon sequences and the lines intron sequences. (Panel B) The in vitro processing products
shown in panel A were analyzed by primer-extension using a 32P-labelled oligodeoxynucleotide primer specific
for sequences in exon 8. Positions of primer extension products corresponding to splice products and intermediates
are indicated.
minutes incubation and increased in intensity with longer incubation times. The product
corresponded to the size of the primer extension product expected if exon 7 was spliced
to exon 8. This was confirmed by direct sequencing of this primer extension product (data
not shown). A shorter primer extension product of approximately 70 nucleotides long
accumulated in a time dependent manner. This product corresponded to a branch point
sequence located 24 nucleotides upstream of the 3' splice site of exon 8, the same branch
5640
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Figure 5. In vitro splicing of exon seven to exon eight (skeletaJ muscle-type splice). (Panel A) Time course
(min) of formation of spliced products from transcripts terminating at the Hindlll site of plasmid pSP65-p7. The
•"P-RNA products were separated in 4% denaturing polyacrylamide gels. Schematic representation of products
are indicated; the boxes represent exon sequences arid the lines intron sequences. Due to the presence of a 3'
exonuclease activity the splice product appears as two bands and is indicated with an asterisk. (Panel B) The
in vitro processing products shown in panel A were analyzed by primer-extension using a 32P-labelled
oligodeoxynucleotide primer specific for sequences in exon 8. Position of primer extension products corresponding
to splice products and intermediates are indicated.
point used for the splicing of exon 6 to exon 8 with the pSP65-p6 Sail substrate (Figure
4). This was confirmed when this product was found to be sensitive to treatment with
debranching activity (see below, Figure 6).
The splicing of the internal alternative exons (exons 6 and 7) to exon 8 involves joining
the alternative 5' splice sites of each of these exons to a common 3' splice site. In addition,
we previously demonstrated using pre-mRNAs derived from pSP64-p2 linearized with Sail,
that exon 5 was efficiently and accurately spliced to exon 8 (31). It was of interest to
determine if splicing of exon 5, as well as exons 6 and 7 to exon 8 involves the use of
5641
Downloaded from https://academic.oup.com/nar/article-abstract/17/14/5633/1058920
by Cold Spring Harbor Laboratory user


















Figure 6. A single branch point is utilized during the splicing of exon five, six or seven to exon eight. Precursors
derived from pSP64-p2 linearized with Sail, pSP65-p6 linearized with Sail, and pSP65-p7 linearized with Hindm
were spliced for 2 h in vitro. The in vitro processing products were analyzed by primer-extension using a 32P-
labelled oligonucleotide primer specific for sequences in the middle of exon 8. Half of the processed RNA was
treated with debranching extract prior to primer-extension analysis. Position of the primer extension products
corresponding to splice products and intermediates are indicated. The primer extension products were separated
on a 8% denaturing polyacrylarrude gel and elcctrophoresed in parallel with dideoxy sequencing reactions performed
using single stranded M B templates primed with the same -"P-labelled oligonucleotide primer to the right. The
sequences corresponding to positions -18 through -31 nucleotides upstream from the 3' splice site and the
corresponding branch nucleotide are indicated.
the same or different branch sites. Precursors derived from pSP64-p2, pSP65-p6, and
pSP65-p7 were spliced in vitro and the products analyzed by primer extension analysis
using a 20 nucleotide long 32P-labelled oligodeoxynucleotide corresponding to sequences
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in the middle of exon 8 (Figure 6). cDNA products of products of branched and debranched
RNA were analyzed on 8% polyacrylamide-8M urea gels along with dideoxy sequence
generated on a single stranded M13 template. Comparison of the dideoxynucleotide sequence
with the primer extension products indicates a single branched nucleotide is utilized that
corresponds to a position 24 nucleotides upstream from the 3' splice site of exon 8. The
bands 8 and 9 nucleotides above the branch site in Figure 6 were not observed in isolated
intermediates and were not believed to be represent authentic branch sites (data not shown).
Thus, splicing of exon 5, 6 or 7 to exon 8 involves the use of the same branch point.
Splicing of exon five to exon seven (skeletal muscle-type splice)
To analyze the branch point used during splicing of exon 5 to exon 7 we used a pre-mRNA
derived from pSP64-p2(7/8) linearized with Sail (Figure 2). We previously demonstrated
that exon 5 is spliced accurately and efficiently to exon 7 in HeLa cell nuclear extracts
using this precursor (31). The products of the in vitro splicing reactions with pre-mRNA
transcripts from pSP64-p2(7/8) linearized with Sail are shown in Figure 7. Following the
splicing reactions the products were divided and a portion loaded on a 4% polyacrylamide-
urea gel (Figure 7a). To map the branch point utilized during the splicing of exon 5 to
exon 7 primer extension experiments were carried using three oligonucleotides
complementary to sequences in the middle of exon 7 (Ex.7), the 3' end of intron 6 (int
6-3 ' ) , and 94-110 nucleotides from the 3' end of intron 6 (intron 6x). Surprisingly,
analysis of the primer extension products using 32P-labelled oligonucleotide primers
complementary to sequences in the middle of exon 7 (Ex.7 primer) or the 3' end of intron
6 (int 6 — 3' primer) revealed a putative branch nucleotide located approximately 190 and
145 nucleotides upstream of these respective primers (Figure 7b). This would correspond
to a lariat branch point located 145 nucleotides upstream of the 3' splice site of exon 7.
To investigate this branch point in greater detail primer extension analysis was performed
using a 32P-labelled oligonucleotide complementary to sequences at the 3' end of intron
6 (Figure 7c). Figure 7c shows the primer extension analysis using the total reaction products
(Figure 7c, lanes 1 and 2) as well as the isolated lariat/exon intermediate (Figure 7c, lanes
3 and 4) and the isolated lariat (Figure 7c, lanes 5 and 6). As indicated, three primer
extension products of 144, 147, and 153 nucleotides were detected using all three RNA
templates. When the primer extension was carried out on debranched RNA the 144, 147
and 153 nucleotide bands disappeared, and a 514 nucleotide band appeared corresponding
to extension to the 5' end of the linearized (debranched) intron. A similar analysis was
performed using a 32P-labelled oligonucleotide complementary to sequences 94 — 110
nucleotides upstream of the 3' splice site of exon 7 (Figure 7d, intron 6x primer). Figure
7d shows the time course of the reaction products analyzed by primer extension using
this primer (lanes 1 through 6). Three products appeared as early as 30 min and accumulated
in a time dependent manner. These three products corresponded to branch point sequences
located 144, 147 and 153 nucleotides upstream of the 3' splice site of exon 8. Based on
the relative intensity of the primer extension stop products the branch point corresponding
to position -147 was found to be the preferred branch nucleotide. The use of this branch
site location was further confirmed when these products were found to be sensitive to
treatment with debranching activity. Figure 7d also shows the primer extension analysis
of the isolated lariat-exon 7/8 intermediate using the same oligonucleotide Qanes 7 and
8). At this level of exposure the expected band of 421 nucleotides corresponding to the
5' end of the linearized intron following treatment with debranching activity is not visible
in this autoradiograph (lane 7). Identical results were also obtained using the isolated lariat
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Figure 7. In vitro splicing of exon five to exon 7 (skeletal muscle-type splice). (Panel A) time course (min)
of formation of spliced products from transcripts terminating at the Sail site of plasrrud pSP64-p2(7/8). The ^P-
RNA products were separated on 4% denaturing polyacrylamide gels. Schematic representation of products and
intermediates are indicated at the left of the panel; from top to bottom, i) pre-mRNA, li) intron/exon intermediate,
iii) free lariat, iv) free lariat but 3' end of intron 6 partly degraded by 3' exonucleolytic activity, v) splice product
and vi) free exon 5. Lane M is markers using pBR322 digested with Mspl. (Panel B) The in vitro processing
products shown in the left panel were analyzed by primer-extension using a -"P-labelled oligodeoxynucleotide
primer complementary to sequences in die middle of exon 7 and a 32P-labelled oligonucleotide primer
complementary to the 3' end on intron 6. Half of the processed RNA was treated with debranching extract prior
to the primer-extension reaction. Position of the extension product corresponding to spliced RNA is indicated.
Lane M is markers using pBR322 digested with Mspl. (Panel C) The in vitro processing products shown in
panel A were analyzed by primer-extension using a primer complementary to the 3' end of intron 6. The positions
of the branch nucleotides are indicated. The total reaction products (lanes 1 and 2) as well as the lariat-exon
7/8 intermediate (lanes 3 and 4) and free lariat (lanes 5 and 6) shown in panel A were isolated and subjected
to primer-extension analysis. Half of the processed RNA was treated with debranching extract prior to the primer-
extension reaction. Position of the extension products are indicated at the left of the panel. Lane M is markers
using pBR322 digested with Mspl. (Panel D) The in vitro processing products shown in panel A were analyzed
by primer-extension using a primer specific for sequences in intron 6 corresponding to nucleotides 94-110
nucleotides upstream from the 3' splice she of exon 7 (intron 6x). The positions of the branch nucleotides are
indicated. The lariat-exon7/8 intermediate shown in panel A was isolated and subjected to primer-extension analysis
using the same ^P-labelled oligodeoxynucleotide. Half of the processed RNA was treated with debranching extract
prior to the primer-extension reaction. Position of the extension products and corresponding DNA sequence is
shown to the left and right of panel, respectively. Lane M is markers using pBR322 digested with Mspl.
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(data not shown). These results confirm that splicing of exon 5 to exon 7 is associated
with the use of branch points located 144-153 nucleotides upstream of the 3' splice site
of exon 7.
DISCUSSION
The present study show some features of branch point selection involved in the utilization
of alternative splice sites in tropomyosin pre-mRNAs including: i) the use of multiple branch
points associated with utilization of each alternative 3' splice site and, ii) the use of branch
points located a long distance (144-153 nucleotides) from the 3' splice site of exon 7
(Figure 8). Splicing of exon 5 to exon 6 (fibroblast-type splice) involved the use of two
adenosine residues and a uridine residue at positions 25, 29, and 36 nucleotides upstream
of the 3' splice site of exon 6. The two adenosine residues appear to be preferred over
the uridine. While most studies have demonstrated the use of an adenosine residue as the
branch acceptor nucleotide, a number of studies have reported that other nucleotides can
participate in branch site formation (56—58). For example, studies of lariat formation in
intron A of human growth hormone pre-mRNA demonstrated that branch point utilization
occurs mainly at a cytidine residue located 28 nucleotides upstream of the 3' splice site,
and to a lesser extent at two uridine residues located 22 and 36 nucleotides upstream from
the 3' splice site (58). The splicing of exon 5 to exon 7 (skeletal muscle-type splice) involves
the use of three branch residues located 144, 147, and 153 nucleotides upstream from
the 3' splice site of exon 7. These results are in contrast to the majority of introns that
have been studied in which only a single adenosine residue, located within 18-40
nucleotides from the 3' splice, site is utilized during lariat formation (7-9,18,59,60).
The most striking observation of the present study was that splicing of exon 5 to exon
7 (skeletal muscle-type splice) was associated with the use of one of three A residues located
144, 147, and 153 nucleotides from the 3' splice site of exon 7 (Figure 7). At present
it is not known if utilization of these branch points play a role in alternative splice site
selection. HeLa cells do not normally carry out this particular splice since the splicing
of exon 5 to exon 7 is specific for skeletal muscle (46). However, we previously
demonstrated that splicing of exon 5 to exon 7 occurred both in vitro and in vivo using
a HeLa cell system using precursors in which exon 7 was first joined to exon 8 (31).
Therefore we believe that splicing of exon 5 to exon 7 in HeLa cells is associated with
the use of branch residues located 144—153 nucleotides upstream of the 3' splice site of
exon 7. Whether these same branch points are utilized in skeletal muscle cells will require
the development of in vitro systems derived from skeletal muscle that accurately reflect
the in vivo splicing observed in this tissue.
The complete sequence of the intron preceding exon 7 is shown in Table I. Inspection
of the 3' end of intron 6 reveals that it contains a number of potential branch site sequences
which are located close to the 3' splice site of exon 7 but are not utilized during the splicing
of exon 5 to exon 7. For example, relatively good branch point consensus sequences are
found at positions 29, 74 and 87 upstream of the 3' splice site. The use of branch point
sequences located 144—153 nucleotides upstream of the 3' splice of exon 7 raises some
intriguing questions regarding the mechanism of branch point selection. As described above,
there are a number of potential branch point residues located relatively close to the 3'
splice site that are not utilized (Table I). Why these sites are not used is not known.
Formation of the branch nucleotide involves the interaction U2 snRNP with the pre-mRNA
branch point (13, 20-22). Mutational analyses demonstrate that the sequences most
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Figure 8. Summary of branch sites utilized in tropomyosin pre-mRNAs. The locations of lariat branch sites used
in tropomyosin splicing are indicated with asterisks. The sequences of the branch sites used in introns 5, 6 and
7 are compared to the lariat branch site consensus sequence in which Y=pyrimidine, R=punne, and N indicates
any of the four nucleotides. Homology to the consensus branch point sequence is indicated. The distance between
each branch site and 3' splice junction is given.
important for the U2 snRNP-branch point interaction are not the nucleotides in the branch
point region itself, but rather the 3' splice site consensus including the polypyrimidine
tract and AG dinucleotide (61 -62). Deletions or mutations in the 3' splice site decrease
or abolish U2 snRNP binding and splicing complex formation (62-65). On the other hand,
mutations in the branch point sequences generally are not associated with the loss of U2
snRNP binding but instead result in activation of cryptic branch points (19,66). These
results demonstrate that the sequences near the 3' splice site are important for the interaction
of U2 snRNP at a given branch point. How sequences in the 3' splice site of intron 6
contribute to branch site selection remains to be determined. One possibility is that the
sequences in intron 6 may establish an RNA conformation that favors the use of particular
branch residues, in this case those located 144-153 nucleotides upstream of the 3' splice
site. Alternatively, factors may interact with sequences within the 3' splice site of exon
7 leading to utilization of a particular branch point. The interaction of factors, such as
U2AF, may regulate the binding of U2 snRNP and lead to utilization of a particular branch
site (23). Since U2AF requires the AG dinucleotide at the 3' splice site, this would require
the interaction of the U2-snRNP with U2AF over a relatively long distance. In addition,
other components may interact with intron 6 that are required for utilization of the 3' splice
site of exon 7.
The use of branch points located a relatively long distance from a 3' splice site may
be an essential feature of some alternatively spliced exons. Alternative splicing of adenovirus
El A RNA was also reported to involve the use of multiple branch points located 51-59
nucleotides from the 3' splice site (34). However, the function of these unusual branch
sites in splice site selection remain to be determined. Recently, studies of alternative splicing
of the rat alpha-tropomyosin gene revealed a novel mechanism involving branch point
selection (67). Alternative splicing of alpha-tropomyosin pre-mRNA involves mutually
exclusive use of exons 2 and 3. Exons 2 and 3 are never spliced together in any cell type.
The intron between exon 2 and exon 3 is 218 nucleotides in length. Interestingly it was
found that the branch point utilized upstream of exon 3 was located 177 nucleotides from
the 3' splice site of this exon. This branch site is only 42 nucleotides from the 5' splice
site of exon 2. As a result exon 2 is unable to splice to exon 3 presumably because the
relatively short distance between the 5' splice site of exon 2 and the downstream branch
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The nucleotide sequence of intron 6 is shown as well as
the locations of the lariat branch sites used in splicing
exon 5 to exon 7 which are indicated with asterisks. The
sequences of branch sites utilized are compared with other
consensus branch point sequences found upstream of the 3'
splice site of exon 7. Y = pyrimidine, R = purine, N
indicates any of the four nucleotide3, nd = not detected.
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results in steric hindrance that prevent splicing factors from interacting with these splice
sites. Such a model cannot alone explain the mutually exclusive use of exon 6 and 7 during
alternative splicing of the rat beta-tropomyosin gene. The lariat branch points located
upstream of exon 7 are 136-147 nucleotides from the 5' splice site of exon 6. At present
the molecular basis for the lack of splicing of exon 6 to exon 7 is unknown.
The regulation of alternative splice site selection will involve the interaction of cellular
factors with specific sequences in a pre-mRNA. Accordingly, those sequences located
between the 3' splice site of exon 7 (skeletal muscle-type splice) and the upstream branch
points may play a role during the regulation of alternative splicing of tropomyosin pre-
mRNAs. For example, these sequences may function by providing a binding site for factors
which regulate tissue-specific splicing. In this respect it is of interest that the 3' end of
intron 6 contains an unusual pyrimidine content (Table I). The region between the first
branch point, located at position —144, and the 3' splice site is approximately 80%
pyrimidines. In addition, the region between - 8 9 through -143 contains a relatively long
pyrimidine-rich tract, containing only 4 purines in this 55 nucleotide long sequence. The
high pyrimidine content of this 3' splice site may play a role in splice site selection. For
example, the polypyrimidine tract immediately downstream of the branch points used in
intron 6 may contribute to the use of these branch point sequences. We have observed
in other tropomyosin genes that undergo alternative splicing that the relevant 3' splice
sites contain long pyrimidine-rich sequences immediately upstream from the 3' splice site
(68-70). These include exons 3, 8, 10 and 11 of the rat alpha-tropomyosin gene (68,69)
and exon 8 of the human slow alpha-tropomyosin gene (70). Furthermore, exon 10 (skeletal
muscle-type splice) of the rat tropomyosin 1 gene contains a long pyrimidine stretch
immediately upstream of the 3' splice site (Erster and Helfman, unpublished observations).
These pyrimidine tracts may represent a cis-acting element involved in the choice of
alternative exons. This hypothesis is supported by recent studies of SV40 early pre-mRNAs
indicating that the pyrimidine content at the 3' splice site had substantial effects on the
alternative splicing in vivo (27). Experiments are in progress to determine the role of the
pyrimidine-rich region upstream of exon 7 in splice site selection and branch site utilization
in tropomyosin pre-mRNAs. Further characterization of the factors involved in use of this
branch site should lead to a better understanding of the general mechanism of branch point
selection and provide clues concerning the regulation of alternative splicing.
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